Dan Leonard

“I'm wondering how you're framing the opportunity around higher sensitivity for Signatera. You now have a couple shots on goal there between Signatera genome, which you haven't talked about in a while, and now the phase variant product as well.”

“And just to follow up on what you're seeing in pharma. You mentioned a mid-single-digit growth in small molecule. Is that all GLP-1s? And can you talk about the situation in pharma outside of GLP-1s?”

“I'd like to talk a little bit about Reveal Therapeutic Monitoring. Helmi, both you and Mike commented on that in your prepared remarks. Could you elaborate further on how you're framing that opportunity both for Reveal volumes as well as for GARDEN 360 volumes as well?”

“I wanted to circle back on the process chromatography comments. I appreciate that there are near-term issues there, but that long-term forecast of mid-single digit growth, what would drive that view?”

“I could just use some help clarifying the growth assumptions for HVP in 2026 and how they compare to 2025. So, you mentioned that the GLP-1 growth will be 10% at the midpoint.”